We are live on ! Find out more
PHAS

PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS

Delisted

PHAS was delisted on the 2nd of November, 2022.

Back to rankings

Fund managers haven’t disclosed any holdings of PHAS yet.

PHAS Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q1 2023, worth a combined $0 — down 100% from $15.6K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of PHAS and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was DAFNA Capital Management, exiting entirely with an estimated $9.69K sold.

  • 0 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q1 2023, down from 5 in Q4 2022.
  • Funds reported $0 of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q1 2023 and 5 closed out, a net change of -5 holders.
  • The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q1 2023 was DAFNA Capital Management, an estimated $9.69K sold.

Based on aggregated 13F filings for Q1 2023.